论文部分内容阅读
目的:探讨卵巢癌患者血浆D-二聚体水平变化的意义及其与临床病理因素的关系。方法:回顾性选择2017年1月至2018年8月浙江省肿瘤医院首次诊治的268例卵巢肿物患者，应用免疫比浊法检测176例卵巢癌患者和92例卵巢良性肿瘤患者的血浆D-二聚体水平，采用单因素和多因素logistic回归分析血浆D-二聚体水平与卵巢癌临床病理因素的关系。结果:卵巢癌患者血浆D-二聚体水平显著高于卵巢良性肿瘤患者(n P<0.001)；单因素分析和多因素logistic回归分析显示，血浆D-二聚体水平与卵巢癌患者的国际妇产科联盟(FIGO)分期密切相关(n P<0.001)；治疗后卵巢癌患者血浆D-二聚体水平明显降低(n P<0.001)。n 结论:卵巢癌患者治疗前存在凝血系统紊乱，血浆D-二聚体水平反映了卵巢癌的恶性程度，与卵巢癌的分期、进展等密切相关，因此D-二聚体水平在卵巢癌血清学诊断和临床应用研究中均有重要价值。“,”Objective:To investigate the plasma D-dimer levels in patients with ovarian cancer, and the relationship between plasma D-dimer and clinical pathologic characteristics of disease.Methods:A total of 268 patients with ovarian tumor who were diagnosed and treated by Zhejiang Cancer Hospital from January 2017 to August 2018 were retrospectively analyzed. Plasma D-dimer levels were measued by immunoturbidimetric assay in 176 ovarian cancer patients and 92 benign ovarian tumor patients. Univariate and multivariate logistic regression were used to analyze the relationship between plasma D-dimer and clinicopathological factors of ovarian cancer.Results:The plasma D-dimer level in patients with ovarian cancer was significantly higher than that in patients with benign ovarian tumor (n P<0.001); univariate analysis and multivariate logistic regression analysis showed that plasma D-dimer was closely related to International Federation of Gynecology and Obstetrics (FIGO) stage of ovarian cancer patients (n P<0.001); the plasma D-dimer level of ovarian cancer patients after treatment was significantly decreased (n P<0.001).n Conclusions:Patients with ovarian cancer has coagulation disorders before treatment. The level of plasma D-dimer reflects the malignant degree of ovarian cancer and is closely related to the stage and progress of ovarian cancer. The level of D-dimer has important value in serological diagnosis and clinical application of ovarian cancer.